How should elevated dehydroepiandrosterone (DHEA) be treated?

Treatment of Elevated DHEA

The management of elevated DHEA depends entirely on identifying and treating the underlying cause—isolated DHEA elevation without associated symptoms or adrenal pathology typically requires no specific treatment, but elevated DHEA in the context of adrenal tumors, virilization, or suspected adrenocortical carcinoma demands immediate evaluation and potential surgical intervention.

Diagnostic Workup

When elevated DHEA is identified, the critical first step is determining whether it represents:

• Adrenocortical carcinoma (ACC): DHEA-S elevation with virilization symptoms strongly suggests ACC, which is responsible for more than half of androgen hypersecretion cases 1
• Functional adrenal adenoma: Benign tumors may secrete excess androgens
• Physiologic variation: Particularly in elderly men where elevated DHEA-S correlates with metabolic syndrome risk 2

Essential Testing

In cases of suspected ACC or clinical virilization, comprehensive androgen testing should be performed 1:

• DHEA-S (dehydroepiandrosterone sulfate)
• Testosterone
• 17β-estradiol
• 17-OH progesterone
• Androstenedione
• 11-deoxycorticosterone
• Progesterone

Imaging is mandatory when adrenal pathology is suspected 1:

• CT imaging with adrenal protocol to assess tumor size, margins, and Hounsfield units
• Malignancy should be suspected if the tumor is larger than 4 cm with irregular margins or internal heterogeneity 1
• MRI with chemical-shift imaging can distinguish benign from malignant tumors, as most benign tumors contain fat while malignant tumors do not 1

Treatment Based on Etiology

Adrenocortical Carcinoma

Surgical resection is the definitive treatment for ACC 1:

• Open adrenalectomy is preferred (not laparoscopic) due to increased risk of local recurrence and peritoneal spread 1
• Complete resection may require removal of adjacent structures including liver, kidney, pancreas, spleen, and/or diaphragm 1
• Adjuvant radiation therapy to the tumor bed should be considered for high-grade tumors, particularly with concern for tumor spillage or close margins 1

Follow-up after ACC resection 1:

• Imaging and biomarker monitoring every 3-6 months
• Serial DHEA-S measurements for functional tumors

Benign Functional Adrenal Adenoma

Laparoscopic adrenalectomy is recommended when feasible 1:

• Indicated for unilateral benign adenomas causing symptomatic androgen excess
• Postoperative corticosteroid supplementation is required until recovery of the hypothalamus-pituitary-adrenal (HPA) axis 1

DHEA Deficiency Context (Not Elevation)

The guidelines address DHEA replacement rather than treatment of elevation:

• DHEA replacement is controversial and should only be considered in women with documented deficiency who have low libido and/or energy despite otherwise adequate hormone replacement 1
• There is insufficient evidence to recommend routine replacement of adrenal androgens in most patients 1

Special Considerations

Metabolic Syndrome Association

In elderly men, elevated DHEA-S correlates with increased metabolic syndrome risk 2:

• The highest DHEA-S quartile showed 2.68-fold increased odds of metabolic syndrome
• This represents an observational association rather than a treatment target
• Management focuses on metabolic syndrome components (hypertension, hyperglycemia, dyslipidemia) rather than DHEA itself

When No Treatment Is Needed

Isolated DHEA elevation without:

• Adrenal mass on imaging
• Clinical signs of virilization
• Other hormonal abnormalities
• Symptoms attributable to androgen excess

Does not require specific intervention beyond:

• Monitoring for development of symptoms
• Repeat imaging if an adrenal lesion is present (per incidentaloma protocols)
• Addressing associated metabolic risk factors if present

Common Pitfalls

• Do not treat DHEA elevation in isolation: Always investigate for underlying adrenal pathology before considering any intervention 1
• Do not use laparoscopic surgery for suspected malignancy: ACC requires open adrenalectomy due to rupture risk 1
• Do not confuse DHEA deficiency with elevation: Guidelines primarily address replacement therapy, not treatment of excess 1
• Do not overlook ACC in young patients with virilization: More than half of androgen hypersecretion cases are due to ACC 1